RT Journal Article
SR Electronic
T1 Effect of SARS-CoV-2 digital droplet RT-PCR assay sensitivity on COVID-19 wastewater based epidemiology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.17.22273949
DO 10.1101/2022.04.17.22273949
A1 Kim, Sooyeol
A1 Wolfe, Marlene K.
A1 Criddle, Craig S.
A1 Duong, Dorothea H.
A1 Chan-Herur, Vikram
A1 White, Bradley J.
A1 Boehm, Alexandria B.
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.17.22273949.abstract
AB We developed and implemented a framework for examining how molecular assay sensitivity for a viral RNA genome target affects its utility for wastewater-based epidemiology. We applied this framework to digital droplet RT-PCR measurements of SARS-CoV-2 and Pepper Mild Mottle Virus genes made using 10 replicate wells, and determined how using fewer wells affected assay sensitivity and its performance for wastewater-based epidemiology applications. We used a computational, downsampling approach. When percent of positive droplets was between 0.024% and 0.5% (as was the case for SARS-CoV-2 genes during the Delta surge), measurements obtained with 3 or more wells were similar to those obtained using 10. When percent of positive droplets was less than 0.024%, then 6 or more wells were needed to obtain similar results as those obtained using 10 wells. When COVID-19 incidence is low, as it was before the Delta surge and SARS-CoV-2 gene concentrations are <104 cp/g, using 6 wells will yield a detectable concentration 90% of the time. Overall, results support an adaptive approach where assay sensitivity is increased by running 6 or more wells during periods of low SARS-CoV-2 gene concentrations, and 3 or more wells during periods of high SARS-CoV-2 gene concentrations.Synopsis Adaptive approaches developed with assay sensitivity in consideration may reduce cost and increase sensitivity for wastewater-based epidemiology.Competing Interest StatementDorothea H. Duong, Vikram Chan-Herur, and Bradley J. White are employees of Verily Life Sciences.Funding StatementThis study was supported by the CDC Foundation, NSF RAPID (CBET-2023057), and by the Epidemiology and Laboratory Capacity for Infectious Diseases Cooperative Agreement (no. 6NU50CK000539-03-02) from CDC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Stanford University determined that this project does not meet the definition of human subject research as defined in federal regulations 45 CFR 46.102 or 21 CFR 50.3 and indicated that no formal IRB review is required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on N and PMMoV gene concentrations are available through the Stanford Digital Repository (https://purl.stanford.edu/km637ys9238). https://purl.stanford.edu/km637ys9238